Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (October 2017)

Friday, November 17, 2017

Between January and October 2017, Russian imported 498.3 bln RUB worth of pharmaceutical drugs (free circulation prices, VAT included), which is in monetary terms 4.2% higher than that of the same period of 2016. Ready-made drugs account for most imports (420 bln RUB), with an 8.9% increase in monetary terms. The in-bulk import has fallen by as much as 15.4%, with 78.2 bln RUB.

In October 2017, the long-term growth rates of import of ready-made drugs were not higher than 5%, while it had been around 13% by August-September. Even before the high season, the market situation does not seem very promising, therefore the players are being careful not to overstock. The import of in-bulk products has increased by 17% against the same period of 2016, which is not that impressive though, considering the devastating 39% fall in September.

In physical terms, the numbers are pretty much the same. Between January and October 20017, Russia imported 1.65 mln worth of ready-made drugs, or around 29.7 bln minimum dosage units (MDU), with a 5.9% rise and a 2.5% fall, respectively. Even though the in-bulk import has risen by 4.3% if calculated in MDU, it does not change the situation drastically, with a 1.8% decrease.

Read more about pharmaceutical drug import to Russia (September performance) here: http://rncph.com/news/13_10_2017

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2016 – October 2017)

Share: